Abeona Therapeutics (ABEO)

$6.56 +0.30 (4.79%)
Market Cap 304.38M
Revenue (ttm) 0.00
Net Income (ttm) -63.73M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.47
Volume 582,939
Avg Vol 1,274,906
Day's Range N/A - N/A
Shares Out 51.16M
Stochastic %K 95%
Beta 1.51
Analysts Strong Sell
Price Target $19.93

Company Profile

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is pz-cel, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based g...

Industry: Biotechnology
Sector: Healthcare
Phone: 646 813 4701
Address:
6555 Carnegie Avenue, 4th Floor, Cleveland, United States
Tain0os
Tain0os Jul. 17 at 6:22 PM
$ABEO nice 15% profit booked here :) $JAZZ hold the door $RARE stabilizing
0 · Reply
kmx_swing
kmx_swing Jul. 17 at 4:04 PM
$ABEO volume will come at $7.40...and it might be massive shot up then...
0 · Reply
tradezha
tradezha Jul. 17 at 4:02 PM
$ABEO been holding since last year - patience..
0 · Reply
kmx_swing
kmx_swing Jul. 17 at 4:02 PM
$ABEO volume is nothing special...less than average...simply put, none is selling
0 · Reply
Pharma3000
Pharma3000 Jul. 17 at 2:25 PM
$ABEO still cheap
0 · Reply
kmx_swing
kmx_swing Jul. 17 at 2:16 PM
$ABEO just two weeks between "wannabe king" and "confirmed idiot"
1 · Reply
Paradise27
Paradise27 Jul. 16 at 8:56 PM
$ABEO New uptrend validated. Weekly MACD reversed to the upside. Fun weeks to come.
1 · Reply
JimiJoJeeter
JimiJoJeeter Jul. 16 at 8:00 PM
$ABEO Looking good...
0 · Reply
fede5910
fede5910 Jul. 16 at 7:05 PM
$ABEO We are one email away from starting to write the new story.
0 · Reply
kmx_swing
kmx_swing Jul. 16 at 4:14 PM
$ABEO could buy back 50% of outstanding shares with money they have 🤣
0 · Reply
Latest News on ABEO
ZEVASKYN™ Gene Therapy Now Available at New Qualified Treatment Center in San Francisco Bay Area

Jul 15, 2025, 7:30 AM EDT - 2 days ago

ZEVASKYN™ Gene Therapy Now Available at New Qualified Treatment Center in San Francisco Bay Area

Bio-Techne's Simple Western™ Technology Utilized in Recent FDA Approval of ZEVASKYN™ Cell-Based Gene Therapy

Jul 14, 2025, 7:00 AM EDT - 3 days ago

Bio-Techne's Simple Western™ Technology Utilized in Recent FDA Approval of ZEVASKYN™ Cell-Based Gene Therapy

TECH

Abeona Therapeutics® Closes Sale of Rare Pediatric Disease Priority Review Voucher for $155 Million

Jul 2, 2025, 7:30 AM EDT - 15 days ago

Abeona Therapeutics® Closes Sale of Rare Pediatric Disease Priority Review Voucher for $155 Million

Abeona Therapeutics® Announces Option Exercise by Beacon Therapeutics for Novel AAV204 Capsid for Ophthalmology Gene Therapy

Jul 1, 2025, 7:30 AM EDT - 16 days ago

Abeona Therapeutics® Announces Option Exercise by Beacon Therapeutics for Novel AAV204 Capsid for Ophthalmology Gene Therapy

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 1, 2025, 7:15 AM EDT - 16 days ago

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Abeona Therapeutics® added to Membership of U.S. Small-cap Russell 2000® Index and Broad-market Russell 3000® Index

Jun 30, 2025, 7:30 AM EDT - 17 days ago

Abeona Therapeutics® added to Membership of U.S. Small-cap Russell 2000® Index and Broad-market Russell 3000® Index

Abeona Therapeutics® Announces Publication in The Lancet of Phase 3 VIITAL™ Study Data in Recessive Dystrophic Epidermolysis Bullosa

Jun 24, 2025, 7:30 AM EDT - 23 days ago

Abeona Therapeutics® Announces Publication in The Lancet of Phase 3 VIITAL™ Study Data in Recessive Dystrophic Epidermolysis Bullosa

Abeona Therapeutics: Substantially Undervalued Post-FDA Approval (Rating Upgrade)

Jun 5, 2025, 5:48 AM EDT - 6 weeks ago

Abeona Therapeutics: Substantially Undervalued Post-FDA Approval (Rating Upgrade)

Abeona Therapeutics® to Present at the Jefferies Global Healthcare Conference

May 30, 2025, 8:46 AM EDT - 6 weeks ago

Abeona Therapeutics® to Present at the Jefferies Global Healthcare Conference

Abeona Therapeutics Inc. (ABEO) Q1 2025 Earnings Call Transcript

May 16, 2025, 1:37 AM EDT - 2 months ago

Abeona Therapeutics Inc. (ABEO) Q1 2025 Earnings Call Transcript

Abeona Therapeutics® Reports First Quarter 2025 Financial Results and Corporate Updates

May 15, 2025, 7:30 AM EDT - 2 months ago

Abeona Therapeutics® Reports First Quarter 2025 Financial Results and Corporate Updates

UPDATE -- Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder

May 14, 2025, 8:07 AM EDT - 2 months ago

UPDATE -- Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder

Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder

May 14, 2025, 7:30 AM EDT - 2 months ago

Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder

Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYNTM Gene Therapy to Treat Wounds in Painful Skin Disorder

May 14, 2025, 7:30 AM EDT - 2 months ago

Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYNTM Gene Therapy to Treat Wounds in Painful Skin Disorder

Abeona Therapeutics® Enters into Agreement to Sell Priority Review Voucher for $155 Million

May 12, 2025, 7:30 AM EDT - 2 months ago

Abeona Therapeutics® Enters into Agreement to Sell Priority Review Voucher for $155 Million

Abeona Surges After FDA Clears First Gene Therapy For Severe Genetic Skin Disease

Apr 30, 2025, 4:41 PM EDT - 2 months ago

Abeona Surges After FDA Clears First Gene Therapy For Severe Genetic Skin Disease

US FDA approves Abeona's skin disorder therapy

Apr 29, 2025, 6:06 AM EDT - 2 months ago

US FDA approves Abeona's skin disorder therapy

U.S. FDA Approves ZEVASKYN™ (prademagene zamikeracel), the First and Only Cell-Based Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Apr 29, 2025, 6:00 AM EDT - 2 months ago

U.S. FDA Approves ZEVASKYN™ (prademagene zamikeracel), the First and Only Cell-Based Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Undercovered Dozen: 3D Systems, Seritage, Topicus, Timken +

Apr 27, 2025, 8:30 AM EDT - 2 months ago

Undercovered Dozen: 3D Systems, Seritage, Topicus, Timken +

DDD TKR KARO NNDM ORC PAA PAGP

Pz-Cel Has Massive Potential For RDEB Patients

Apr 21, 2025, 10:00 AM EDT - 3 months ago

Pz-Cel Has Massive Potential For RDEB Patients

Abeona Therapeutics: A Buy With Major PDUFA Catalyst On April 29 That Should Send Shares Higher

Apr 12, 2025, 11:39 AM EDT - 3 months ago

Abeona Therapeutics: A Buy With Major PDUFA Catalyst On April 29 That Should Send Shares Higher

Abeona Therapeutics Inc. (ABEO) Q4 2024 Earnings Call Transcript

Mar 20, 2025, 3:20 PM EDT - 4 months ago

Abeona Therapeutics Inc. (ABEO) Q4 2024 Earnings Call Transcript

Abeona Therapeutics® Reports Full Year 2024 Financial Results, Provides Pz-cel Regulatory Update and Commercial Launch Plans

Mar 20, 2025, 7:30 AM EDT - 4 months ago

Abeona Therapeutics® Reports Full Year 2024 Financial Results, Provides Pz-cel Regulatory Update and Commercial Launch Plans

Abeona Therapeutics® to Present at the Leerink Partners Global Healthcare Conference

Mar 4, 2025, 9:00 AM EST - 4 months ago

Abeona Therapeutics® to Present at the Leerink Partners Global Healthcare Conference

Abeona Therapeutics: Despite Some Competitive Pressure, This Looks Undervalued

Jan 24, 2025, 12:40 PM EST - 6 months ago

Abeona Therapeutics: Despite Some Competitive Pressure, This Looks Undervalued

Abeona Therapeutics® Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

Nov 14, 2024, 7:30 AM EST - 8 months ago

Abeona Therapeutics® Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

Abeona Therapeutics® Announces FDA Acceptance of BLA Resubmission of Pz-cel for the Treatment of Recessive Dystrophic Epidermolysis Bullosa

Nov 12, 2024, 7:30 AM EST - 8 months ago

Abeona Therapeutics® Announces FDA Acceptance of BLA Resubmission of Pz-cel for the Treatment of Recessive Dystrophic Epidermolysis Bullosa

Abeona Therapeutics® Announces Participation in November Investor Conferences

Nov 4, 2024, 7:30 AM EST - 9 months ago

Abeona Therapeutics® Announces Participation in November Investor Conferences

Abeona Therapeutics® Completes Pz-cel Biologics License Application Resubmission to U.S. Food and Drug Administration

Oct 29, 2024, 7:30 AM EDT - 9 months ago

Abeona Therapeutics® Completes Pz-cel Biologics License Application Resubmission to U.S. Food and Drug Administration

Abeona Therapeutics Targets RDEB Market With Promising Pz-cel Therapy

Oct 3, 2024, 8:09 AM EDT - 10 months ago

Abeona Therapeutics Targets RDEB Market With Promising Pz-cel Therapy

Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences

Sep 3, 2024, 7:30 AM EDT - 11 months ago

Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences

Abeona Therapeutics® Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD to its Board of Directors

Aug 14, 2024, 7:30 AM EDT - 1 year ago

Abeona Therapeutics® Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD to its Board of Directors

Abeona Therapeutics® Announces Favorable Medicare Reimbursement Decisions for Pz-cel

Aug 13, 2024, 7:30 AM EDT - 1 year ago

Abeona Therapeutics® Announces Favorable Medicare Reimbursement Decisions for Pz-cel

Abeona Therapeutics® Reports Second Quarter 2024 Financial Results and Concludes Type A Meeting with FDA to Align on Upcoming Pz-cel BLA Resubmission

Aug 12, 2024, 7:30 AM EDT - 1 year ago

Abeona Therapeutics® Reports Second Quarter 2024 Financial Results and Concludes Type A Meeting with FDA to Align on Upcoming Pz-cel BLA Resubmission

Abeona: BLA Resubmission Of Pz-Cel Gets Ball Rolling Towards Other Milestones

Jul 12, 2024, 4:59 PM EDT - 1 year ago

Abeona: BLA Resubmission Of Pz-Cel Gets Ball Rolling Towards Other Milestones

Abeona Therapeutics and Beacon Therapeutics Announce Non-Exclusive Agreement for Beacon to Evaluate Therapeutic Potential of Abeona's Patented AAV204 Capsid for Select Ophthalmology Indications

Jul 11, 2024, 7:30 AM EDT - 1 year ago

Abeona Therapeutics and Beacon Therapeutics Announce Non-Exclusive Agreement for Beacon to Evaluate Therapeutic Potential of Abeona's Patented AAV204 Capsid for Select Ophthalmology Indications

Abeona Therapeutics to Present at the Stifel Virtual Cell Therapy Forum

Jul 8, 2024, 7:30 AM EDT - 1 year ago

Abeona Therapeutics to Present at the Stifel Virtual Cell Therapy Forum

Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 3, 2024, 7:30 AM EDT - 1 year ago

Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Abeona Therapeutics to Present at the Jefferies Global Healthcare Conference

May 28, 2024, 7:30 AM EDT - 1 year ago

Abeona Therapeutics to Present at the Jefferies Global Healthcare Conference

Abeona Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Progress

May 15, 2024, 7:30 AM EDT - 1 year ago

Abeona Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Progress

Abeona Therapeutics Announces Pricing of $75 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

May 3, 2024, 7:30 AM EDT - 1 year ago

Abeona Therapeutics Announces Pricing of $75 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Buying The Dip In Abeona Therapeutics After The Recent Manufacturing-Related CRL

May 2, 2024, 5:50 PM EDT - 1 year ago

Buying The Dip In Abeona Therapeutics After The Recent Manufacturing-Related CRL

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Abeona Therapeutics Inc. (ABEO) on Behalf of Investors

May 2, 2024, 11:00 AM EDT - 1 year ago

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Abeona Therapeutics Inc. (ABEO) on Behalf of Investors

The Law Offices of Frank R. Cruz Announces Investigation of Abeona Therapeutics Inc. (ABEO) on Behalf of Investors

Apr 29, 2024, 7:11 PM EDT - 1 year ago

The Law Offices of Frank R. Cruz Announces Investigation of Abeona Therapeutics Inc. (ABEO) on Behalf of Investors

Abeona Therapeutics Tanks On CRL From The FDA, But All Hope Is Not Lost

Apr 23, 2024, 5:20 PM EDT - 1 year ago

Abeona Therapeutics Tanks On CRL From The FDA, But All Hope Is Not Lost

US FDA declines to approve Abeona's skin disorder treatment

Apr 22, 2024, 4:31 PM EDT - 1 year ago

US FDA declines to approve Abeona's skin disorder treatment

Abeona Therapeutics Provides Regulatory Update on Pz-cel

Apr 22, 2024, 4:05 PM EDT - 1 year ago

Abeona Therapeutics Provides Regulatory Update on Pz-cel

Tain0os
Tain0os Jul. 17 at 6:22 PM
$ABEO nice 15% profit booked here :) $JAZZ hold the door $RARE stabilizing
0 · Reply
kmx_swing
kmx_swing Jul. 17 at 4:04 PM
$ABEO volume will come at $7.40...and it might be massive shot up then...
0 · Reply
tradezha
tradezha Jul. 17 at 4:02 PM
$ABEO been holding since last year - patience..
0 · Reply
kmx_swing
kmx_swing Jul. 17 at 4:02 PM
$ABEO volume is nothing special...less than average...simply put, none is selling
0 · Reply
Pharma3000
Pharma3000 Jul. 17 at 2:25 PM
$ABEO still cheap
0 · Reply
kmx_swing
kmx_swing Jul. 17 at 2:16 PM
$ABEO just two weeks between "wannabe king" and "confirmed idiot"
1 · Reply
Paradise27
Paradise27 Jul. 16 at 8:56 PM
$ABEO New uptrend validated. Weekly MACD reversed to the upside. Fun weeks to come.
1 · Reply
JimiJoJeeter
JimiJoJeeter Jul. 16 at 8:00 PM
$ABEO Looking good...
0 · Reply
fede5910
fede5910 Jul. 16 at 7:05 PM
$ABEO We are one email away from starting to write the new story.
0 · Reply
kmx_swing
kmx_swing Jul. 16 at 4:14 PM
$ABEO could buy back 50% of outstanding shares with money they have 🤣
0 · Reply
Zaga64
Zaga64 Jul. 16 at 2:00 PM
$ABEO Easy $$$ ABEO and CHRS Both companies should take advantage of the ridicules low sp and start a buyback program.
0 · Reply
invest2021_now
invest2021_now Jul. 16 at 12:41 PM
$ABEO Patience!! Its time is coming!
0 · Reply
Paradise27
Paradise27 Jul. 15 at 9:40 PM
$ABEO Shorts think ABEO won’t execute, but as they announce more hospitals support for Zevaskyn, booked procedures and early success the short theory will falter and they will have to cover. Abeona Therapeutics (ABEO) has a short interest of 8.29 million shares, representing 18.30% of the float. Possible squeeze on good news.
1 · Reply
SeeKingProphet
SeeKingProphet Jul. 15 at 7:25 PM
$ABEO now that things are quiet around here we can move up
0 · Reply
Zaga64
Zaga64 Jul. 15 at 3:50 PM
$ABEO Bios under short attack but ABEO is holding strong today.
1 · Reply
JBio
JBio Jul. 15 at 3:06 PM
$XBI is down 2%. $ABEO Great news about the new QC. August is coming 🚀
0 · Reply
alexpitti
alexpitti Jul. 15 at 1:56 PM
New center $ABEO down 1%. A nice smack in the face on good news
2 · Reply
Filvul
Filvul Jul. 15 at 1:17 PM
$ABEO
0 · Reply
SeeKingProphet
SeeKingProphet Jul. 15 at 12:52 PM
$ABEO get ready for the upgrades ⬆️
0 · Reply
kmx_swing
kmx_swing Jul. 15 at 12:33 PM
$ABEO that is nice surprise. I was thinking only Chicago will do..But they start both with California...that means a lot = big trust inside hospital, big will to serve patients which must queue for this help and evidently good attitude and coverage by insurers...Off to the races now...The show is officialy on!
1 · Reply
bigicica
bigicica Jul. 15 at 12:21 PM
$ABEO ZEVASKYN™ Gene Therapy Now Available at New Qualified Treatment Center in San Francisco Bay Area
0 · Reply
Quantumup
Quantumup Jul. 14 at 7:55 PM
H.C. Wainwright reiterated $ABEO Buy-$20 after $RARE's CRL for UX111 F/K/A ABO-102 — views $RARE's UX111 as remaining eminently approvable — $ABEO would be entitled to royalties on net sales of this candidate if approved — notes that its valuation assessment does not factor in any such royalties and accordingly the CRL does not impact their thesis. H.C. Wainwright said in its note to investors:
0 · Reply